Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07301268CT.gov GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | — | Recruiting | — | — | — |
NCT05465954CT.gov Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | — | Recruiting | — | — | — |
NCT05084430CT.gov Study of Pembrolizumab and M032 (NSC 733972) | — | Recruiting | — | — | — |
NCT03197506CT.gov Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT02798406CT.gov Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | — | Completed | — | — | — |
NCT02502708CT.gov Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | — | Completed | — | — | — |
NCT02337686CT.gov Pembrolizumab in Treating Patients With Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT02186509CT.gov Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | — | Completed | — | — | — |
NCT01903330CT.gov ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | — | Active Not Recruiting | — | — | — |
NCT01454596CT.gov CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00641706CT.gov Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00611325CT.gov Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gliosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Mayo Clinic | P2 | BB · 67 |
| Cediranib | Northwestern University | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | University Hospital, Geneva | P2 | BB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
| Tandutinib | National Cancer Institute (NCI) | P2 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
| Irinotecan | RTOG Foundation, Inc. | P3 | BB |
+42 more in the Gliosarcoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CediranibNorthwestern UniversityBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- SorafenibUniversity Hospital, GenevaBB
- GefitinibNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Cyclophosphamide in Gliosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-gliosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →